Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Discovery of novel therapeutic opportunities for EOC is important for the improvement of clinical outcome of the patients. Emerging evidence is suggesting that epithelial-mesenchymal transition (EMT) plays a crucial role in t...

Full description

Saved in:
Bibliographic Details
Published inCurrent drug targets Vol. 13; no. 13; p. 1649
Main Authors Huang, Ruby Yun-Ju, Chung, Vin Yee, Thiery, Jean Paul
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.12.2012
Subjects
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - metabolism
Carcinoma, Ovarian Epithelial
Drug Delivery Systems - trends
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - physiology
Epithelial-Mesenchymal Transition - drug effects
Epithelial-Mesenchymal Transition - physiology
Female
Humans
Neoplasm Invasiveness - genetics
Neoplasms, Glandular and Epithelial - drug therapy
Neoplasms, Glandular and Epithelial - metabolism
Neoplasms, Glandular and Epithelial - pathology
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - metabolism
Ovarian Neoplasms - pathology
Online AccessGet more information

Cover

More Information
Summary:Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Discovery of novel therapeutic opportunities for EOC is important for the improvement of clinical outcome of the patients. Emerging evidence is suggesting that epithelial-mesenchymal transition (EMT) plays a crucial role in the aggressiveness in EOC including increasing migration and invasion ability, contributing to chemoresistance and cancer stem cell populations. Targeting EMT in EOC thus offers an attractive therapeutic option.
ISSN:1873-5592
DOI:10.2174/138945012803530044